Discontinued — last reported Q2 '24
Bristol-Myers Squibb AFS Securities increased by 17.3% to $406.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 25.3%, from $324.00M to $406.00M.
An increase reflects capital allocation toward investment portfolios, while a decrease may signal portfolio rebalancing or asset liquidation.
Available-for-sale securities are debt or equity investments that are not classified as trading or held-to-maturity, and...
Common in the investment portfolios of banks and insurance companies.
fin_afs_securities| Q4 '22 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $364.00M | $367.00M | $357.00M | $324.00M | $320.00M | $344.00M | $346.00M | $406.00M |
| QoQ Change | — | — | +0.8% | -2.7% | -9.2% | -1.2% | +7.5% | +0.6% | +17.3% |
| YoY Change | — | — | — | — | — | -12.1% | -6.3% | -3.1% | +25.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.